Bronchiectasis drugs are primarily used to treat chronic bronchial infections. These drugs help improve lung functioning by reducing infections and controlling inflammation. Commonly prescribed medications include antibiotics, bronchodilators, mucolytics, and chest physiotherapy.
The global Bronchiectasis Drugs Market is estimated to be valued at US$ 303.8 Mn or Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030 , as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the bronchiectasis drugs market is the growing preference for combination therapies. Combination therapies using two or more drugs are becoming increasingly common for managing bronchiectasis. For example, combining macrolide antibiotics like azithromycin with inhaled corticosteroids has shown improved efficacy in reducing exacerbations compared to monotherapy. The synergistic effects of combination drugs help better control both infections and inflammation associated with bronchiectasis.
Segment Analysis
The Global Bronchiectasis Drugs Market Size is segmented based on drug class, distribution channel, and region. Based on drug class, the market is segmented into antibiotics and expectorants. The antibiotics segment dominated the market in 2022 and is expected to continue its dominance over the forecast period. Antibiotics are commonly used as the first line of treatment to control symptoms and prevent disease progression in bronchiectasis patients.
Key Takeaways
The global bronchiectasis drugs market is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing respiratory infections and awareness programs conducted by various NGOs.
Regional analysis
North America dominated the bronchiectasis drugs market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to rising research activities for novel treatment options and presence of well-established healthcare infrastructure and key market players in the region.
Key players
Key players operating in the bronchiectasis drugs market are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., and Insmed Incorporated.
For More Insights, Read- https://www.newsstatix.com/bronchiectasis-drugs-market-size-share-analysis-2023-2030/
